rp-l401
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04525352)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Pyruvate kinase isozymes R/LSupplementation
PKLR supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04525352 | Phase 1 | Oct 31, 2020 | California Institute for Regenerative Medicine (CIRM), Rocket Pharma Limited, University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Rocket Pharma Limited | For profit | 1 | 1 | 1 | 2020 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1